Opioid Use Disorder Management

Introduction to Buprenorphine Administration

Buprenorphine can be used to treat opioid use disorder, but it should only be administered to patients in active opioid withdrawal, as confirmed by history and physical examination, due to the risk of inducing significant withdrawal symptoms in patients currently under the influence of opioids, as recommended by the American College of Emergency Physicians 1
The American College of Emergency Physicians and the CDC recommend offering or arranging evidence-based treatment, usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies, for patients with opioid use disorder 2, 1

Buprenorphine may be considered for initiation in the emergency department after a patient has been stabilized from acute overdose, with the goal of treatment of opioid use disorder as maintenance therapy, as recommended by the American College of Emergency Physicians 1
Buprenorphine has a ceiling effect on respiratory depression, providing greater safety compared to full agonists, as supported by the CDC recommendation for its use in opioid use disorder treatment 2
Clinical trials are still needed to evaluate the effectiveness and safety of treating emergency department patients in opioid withdrawal with buprenorphine, highlighting the need for further research in this area 1

For patients already on buprenorphine maintenance therapy who develop acute pain, approaches exist such as continuing buprenorphine and titrating short-acting opioid analgesics, dividing the daily buprenorphine dose and administering every 6-8 hours, or discontinuing buprenorphine and treating with full opioid agonists, according to the American College of Physicians 3
Higher doses of morphine will be required to overcome buprenorphine's receptor blockade, and naloxone should be available and respiratory status must be closely monitored due to variable dissociation rates 4
Increasing the buprenorphine dose in divided doses, with dosing ranges of 4-16 mg divided into doses every 8 hours, can show benefit in patients with non-oncologic chronic pain 4
If the maximum buprenorphine dose is reached, a trial of an additional potent, long-acting opioid such as fentanyl, morphine, or hydromorphone should be considered 4

Buprenorphine has a high affinity for μ-opioid receptors, which can block the analgesic effects of full opioid agonists like morphine and potentially precipitate withdrawal symptoms, with a slow dissociation rate that prolongs its blocking effect 3
The American College of Physicians recommends approaching the concurrent use of buprenorphine and morphine with extreme caution and only under close medical supervision due to complex pharmacological interactions and potential for adverse effects 3
Mixed opioid agonist-antagonist analgesics such as pentazocine, nalbuphine, and butorphanol should be avoided as they can displace the maintenance opioid from the μ-receptor and precipitate acute withdrawal 3
For hospitalized patients with acute pain, convert buprenorphine to methadone at 30-40 mg/day, as methadone binds less tightly to μ-receptors, allowing more predictable response to additional opioid analgesics 3
For patients with both chronic pain and OUD, transdermal buprenorphine may provide better analgesia than sublingual formulations 4
For patients in maintenance therapy with buprenorphine and inadequate analgesia despite the aforementioned strategies, transitioning the patient from buprenorphine to methadone maintenance is recommended 4